The page says data are expected by mid-2027. Arcus Biosciences develops therapies for cancer, inflammatory and autoimmune diseases; Summit Therapeutics Inc. focuses on oncology therapies.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).
Summit Therapeutics Inc. announced an updated overall survival analysis from the Phase III HARMONi trial, reporting an overall survival hazard ratio of 0.76 in Western patients, consistent with Asian patients.
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing medicinal therapies intended to improve quality of life, increase potential duration of life, and address serious unmet medical needs.
The company aims to build a health care organization overseeing therapy design and development, clinical trials and enrollment, regulatory submissions and approvals, and commercialization.
